Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies